Vir Biotechnology (VIR) is back on investor radars after the Board expanded to eight members and appointed experienced biotechnology executive Timothy Coughlin as both director and Audit Committee Chair, effective June 9, 2026.

The boardroom reshuffle is landing against a mixed trading backdrop, with the share price at US$8.25 and recent weakness, including a 30 day share price return down 11.19%, contrasting with a year to date share price return up 38.89% and a 1 year total shareholder return of 57.14%. However, the 3 and 5 year total shareholder returns remain deeply negative, indicating longer term holders have experienced heavy declines.

If news around Vir has you rethinking the sector, this could be a useful moment to scan other biotech and pharma names using our healthcare AI stock screener, starting with 39 healthcare AI stocks.

With the stock at US$8.25, recent double digit gains over the past year, a value score of 1 and analyst targets implying a very large upside, investors have to ask: is there still mispricing here, or is the market already factoring in future growth?

Most Popular Narrative: 60.1% Undervalued

Analysts following Vir Biotechnology see fair value at $20.67 per share compared with the last close at $8.25, which creates a wide gap investors will notice.

The strong foundational patent rights to the PRO-XTEN platform enable expansion into additional high-value oncology indications, potentially increasing earnings through diversification and broadening revenue streams. Significant progress has been made in oncology with promising T-cell engager therapies for colorectal and prostate cancers, suggesting future revenue increases from novel oncology treatments.

Want to see what underpins that valuation gap? The narrative leans on rapid revenue expansion, margin improvement and a rich future earnings multiple. Curious which assumptions really drive that $20.67 figure?

Result: Fair Value of $20.67 (UNDERVALUED)

However, this hinges on unproven therapies clearing clinical and regulatory hurdles, and any setback in trials or approvals could quickly challenge the bullish valuation story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Mixed signals around valuation and execution risks can make Vir Biotechnology a tricky call, so consider acting while sentiment is still forming and weigh both sides with the 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If you do not broaden your watchlist beyond a single stock, you may miss opportunities that better fit your goals, risk comfort and time horizon.

• Spot potential bargains early by scanning screener containing 20 high quality undiscovered gems that combine quality fundamentals with quieter market attention.
• Strengthen portfolio resilience by focusing on companies in the solid balance sheet and fundamentals stocks screener (46 results) that pair healthier debt levels with sound financial footing.
• Dial down volatility by filtering for 63 resilient stocks with low risk scores that score well on stability, so sudden shocks are less likely to catch you off guard.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.